Minerva Neurosciences | NERV - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Adma Biologics USD 138.15M 50.52M 2026-03
ALKERMES USD 351.55M 37.02M 2026-03
Alterity Therapeutics Limited AUD 15.77M 9.56M 2023-06
AstraZeneca USD 7.56B 1.85B 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Cipla INR 7.96B 39.9M 2025-09
Clal Biotechnology ILS 5.73M 1.71M 2023-12
Compugen USD 90.6M 83.14M 2025-12
CSL USD 2.16B 633M 2025-06
Eli Lilly USD 5.28B 1.99B 2026-03
Esperion Therapeutics USD 156.16M 11.69M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Grifols EUR 979.78M 334.84M 2024-12
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
J&J USD 21.69B 1.98B 2026-03
Merck USD 5.33B 9.24B 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03
Novavax USD 228.36M 12.27M 2026-03
Pfizer USD 1.7B 561M 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12